drugset

drugset / Trial / NCT01124565

Safety Study of Two Repeat Doses of RT001 for the Treatment of Moderate to Severe Lateral Canthal Lines in Adults

NCT01124565 ↗

Phase 2 Completed 40 enrolled Revance Therapeutics, Inc.

NaSingle-groupOpen-labelTreatment

Summary

This study's objective is to evaluate if RT001 is safe and well-tolerated following two (2) sequential applications.

Timeline

Start: 2010-05
Primary completion: 2010-07
Completion: 2010-07

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	RT001	Protein / enzyme biologic	—	Topical

Indications